NRG Oncology NRG-GI007 trial-in-progress: Phase I study of OBP-301 (Telomelysin) and definitive chemoradiation (CRT) for patients with locally advanced esophageal and gastroesophageal adenocarcinoma who are not candidates for surgery.Geoffrey Y. Ku, Theodore S. Hong, Kathryn Winter et al.|Journal of Clinical Oncology|2021Cited by 1
Initial safety assessment of the endoscopically injected oncolytic virus OBP-301 in medically inoperable esophageal cancer: NRG-GI007.Geoffrey Y. Ku, Theodore S. Hong, Eric D. Miller et al.|Journal of Clinical Oncology|2024Cited by 1
NRG-GI007: Secondary endpoints of safety assessment and clinical complete response (cCR) of chemoradiation with endoscopically injected oncolytic virus OBP-301 in medically inoperable esophageal cancer.Geoffrey Y. Ku, Theodore S. Hong, Jennifer Moughan et al.|Journal of Clinical Oncology|2025Cited by 0
NRG-GI007: Phase 1 Study of OBP-301, An Oncolytic Virus, and Definitive Chemoradiation in Locally Advanced Esophageal CancerGeoffrey Y Ku, Terence M Williams, Kathryn Winter et al.|International Journal of Radiation Oncology*Biology*Physics|2026Cited by 0